ACYLGUANIDINE DERIVATIVE OR SALT THEREOF

It is intended to provide a compound which can be used for preventing and/or treating a disease associated with 5HT2B receptor and 5HT7 receptor, particularly for treating irritable bowel syndrome (IBS) and/or preventing migraine. It was found that an acylguanidine derivative characterized by having...

Full description

Saved in:
Bibliographic Details
Main Authors ITAHANA HIROTSUNE, NOZAWA EISUKE, HARADA KOICHIRO, YAMADA HIROYOSHI, MORITOMO AYAKO, MATSUZAWA TAKAHO, AKUZAWA SHINOBU
Format Patent
LanguageEnglish
Published 20.05.2008
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:It is intended to provide a compound which can be used for preventing and/or treating a disease associated with 5HT2B receptor and 5HT7 receptor, particularly for treating irritable bowel syndrome (IBS) and/or preventing migraine. It was found that an acylguanidine derivative characterized by having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5HT2B receptor and 5HT7 receptor. In addition, the compound of the invention having the antagonism to both receptors showed a better pharmacological action compared to the case where an antagonist selective to one of the receptors was solely used. From the above results, the compound of the invention is useful for preventing and/or treating a disease associated with 5HT2B receptor and 5HT7 receptor, particularly for treating irritable bowel syndrome (IBS) and/or preventing migraine.
Bibliography:Application Number: KR20087005637